Welcome to the genitourinary (GU) cancer channel. Explore the latest updates in GU cancer, including expert interviews from major international congresses and news by subtype.

Genitourinary cancer is any cancer of the genitourinary system, including the bladder, prostate, kidneys, testicles, penis, ureter and adrenal glands. The treatment of these cancers are managed by urologists and/or oncologists, depending upon the type of treatment. Minimally-invasive techniques, as well as traditional chemoradiotherapy are utilized.

Exciting advances are being made in the field of genitourinary cancer, including checkpoint inhibitor treatments, new non-steroidal anti-androgens, chemoimmunotherapy combinations and predictive biomarkers.

Genitourinary Cancer

The Genitourinary Cancer Channel on VJOncology is supported by a grant from Pfizer Inc and Merck KGaA.

The supporters have no influence over the production of the content.

If you are interested in becoming a supporter of The Genitourinary Cancer Channel, please contact us

Genitourinary Cancer

Welcome to the genitourinary (GU) cancer channel. Explore the latest updates in GU cancer, including expert interviews from major international congresses and news by subtype.

Genitourinary cancer is any cancer of the genitourinary system, including the bladder, prostate, kidneys, testicles, penis, ureter and adrenal glands. The treatment of these cancers are managed by urologists and/or oncologists, depending upon the type of treatment. Minimally-invasive techniques, as well as traditional chemoradiotherapy are utilized.

Exciting advances are being made in the field of genitourinary cancer, including checkpoint inhibitor treatments, new non-steroidal anti-androgens, chemoimmunotherapy combinations and predictive biomarkers.

View all videos
The Genitourinary Cancer Channel on VJOncology is supported by a grant from Pfizer Inc and Merck KGaA.

The supporters have no influence over the production of the content.

If you are interested in becoming a supporter of The Genitourinary Cancer Channel, please contact us

Latest videos OncoAlert Colloquium Subtypes Topics Conferences Features Editorial Board

GU Cancer Videos by Subtype

Prostate Cancer
Bladder Cancer
Kidney Cancer
Testicular Cancer
Penile Cancer
3:43
The history of biomarkers in the treatment of prostate cancer
Howard Scher • 18 Feb 2021
8:53
Prognostic biomarkers to guide treatment of mCRPC
Howard Scher • 18 Feb 2021
3:56
CTC enumeration as a prognostic biomarker in prostate cancer
Howard Scher • 18 Feb 2021
5:30
Clinical outcomes and genomic correlates of African Americans with mCSPC
Pedro Barata • 16 Feb 2021
View All Videos
3:46
Optimizing gemcitabine in metastatic TNBC
Nathan M. Merrill • 9 Apr 2021
3:12
IMvigor130: OS data for atezolizumab plus chemo versus chemo alone
Enrique Grande • 6 Apr 2021
2:15
Key findings on atezolizumab for mUC from IMvigor130
Enrique Grande • 6 Apr 2021
3:05
CA 125, CA19-9 and CEA: tumor markers in bladder cancer
Siamak Daneshmand • 18 Feb 2021
View All Videos
5:30
Angiogenic and T-effector subgroups and propensity for PBRM1 and BAP1 alterations in ccRCC
Pedro Barata • 16 Feb 2021
4:44
VEGFR inhibitors with immune checkpoint inhibitors for advanced renal cancer
Tian Zhang • 17 Feb 2021
2:35
PAPMET: MET inhibitors in treating papillary renal cell carcinoma
Tian Zhang • 17 Feb 2021
5:10
CheckMate 214: patterns of progression with nivolumab plus ipilimumab versus sunitinib for RCC
Rana McKay • 17 Feb 2021
View All Videos
1:50
Current treatment landscape of seminoma
Siamak Daneshmand • 18 Feb 2021
3:18
SEMS: surgery as first-line therapy for seminoma
Siamak Daneshmand • 18 Feb 2021
3:00
Impact of telemedicine on patient-reported outcomes in urologic oncology
John Gore • 11 Feb 2021
2:54
Risk stratification in metastatic seminoma
Peter Albers • 13 Feb 2020
View All Videos
Penile cancer: avelumab
Srikala Sridhar • 13 Feb 2020
3:07
Vinflunine shows a chemotherapeutic advantage for locally-advanced and metastatic penile cancer
Lisa Pickering • 8 Feb 2018
2:38
The current treatment landscape for penile cancer
Lisa Pickering • 8 Feb 2018
View All Videos

Topics

Trial Updates
Treatment
Immuno-Oncology
Diagnosis
Imaging
3:54
Guadecitabine + atezolizumab in mUC who have progressed after initial checkpoint inhibitor therapy
Elizabeth Plimack • 7 Apr 2021
3:12
IMvigor130: OS data for atezolizumab plus chemo versus chemo alone
Enrique Grande • 6 Apr 2021
2:15
Key findings on atezolizumab for mUC from IMvigor130
Enrique Grande • 6 Apr 2021
3:18
SEMS: surgery as first-line therapy for seminoma
Siamak Daneshmand • 18 Feb 2021
View All Videos
3:46
Optimizing gemcitabine in metastatic TNBC
Nathan M. Merrill • 9 Apr 2021
3:12
IMvigor130: OS data for atezolizumab plus chemo versus chemo alone
Enrique Grande • 6 Apr 2021
2:15
Key findings on atezolizumab for mUC from IMvigor130
Enrique Grande • 6 Apr 2021
1:50
Current treatment landscape of seminoma
Siamak Daneshmand • 18 Feb 2021
View All Videos
3:54
Guadecitabine + atezolizumab in mUC who have progressed after initial checkpoint inhibitor therapy
Elizabeth Plimack • 7 Apr 2021
3:12
IMvigor130: OS data for atezolizumab plus chemo versus chemo alone
Enrique Grande • 6 Apr 2021
2:15
Key findings on atezolizumab for mUC from IMvigor130
Enrique Grande • 6 Apr 2021
0:57
Areas of unmet need for patients with advanced UC
Elizabeth Plimack • 7 Apr 2021
View All Videos
1:35
BARCODE1: polygenic risk score for targeted screening for prostate cancer
Jana McHugh • 15 Feb 2021
3:13
18F-DCFPyL PET/CT imaging up-stages patients with prostate cancer
Frédéric Pouliot • 15 Feb 2021
4:55
18F-fluciclovine PET in mCRPC treated with abiraterone acetate
Pedro Barata • 16 Feb 2021
2:50
The impact of COVID-19 on genitourinary cancer care
John Gore • 11 Feb 2021
View All Videos
2:42
Latest updates in PSMA imaging for prostate cancer
Declan Murphy • 9 Feb 2021
1:25
Improving precision of high-quality prostate cancer MRI
Anwar Padhani • 14 Oct 2020
4:15
PSMA-PET for patients with high-risk for de novo N1 disease
Jeremie Calais • 9 Oct 2020
5:52
Future of imaging and theranostics in prostate cancer
Jeremie Calais • 9 Oct 2020
View All Videos

Conferences

GU Cancers 2021
PROSCA/BLADDR 2020
ESMO 2020
ASCO 2020
GU Cancers 2020
1:50
Current treatment landscape of seminoma
Siamak Daneshmand • 18 Feb 2021
3:05
CA 125, CA19-9 and CEA: tumor markers in bladder cancer
Siamak Daneshmand • 18 Feb 2021
3:18
SEMS: surgery as first-line therapy for seminoma
Siamak Daneshmand • 18 Feb 2021
3:43
The history of biomarkers in the treatment of prostate cancer
Howard Scher • 18 Feb 2021
View All Videos
0:53
Immunotherapy in prostate cancer
Emmanuel Seront • 7 Oct 2020
1:35
Unmet needs in mHSPC
Ursula Vogl • 7 Oct 2020
1:29
Genomic testing in prostate cancer
Emmanuel Seront • 7 Oct 2020
0:38
Second-line treatment of mHSPC
Ursula Vogl • 7 Oct 2020
View All Videos
6:14
ESMO highlights: 705MO study in GU cancer
Pavlos Msaouel • 19 Sep 2020
3:11
PRS-343 in HER2-Positive Solid Tumors: A trial update
Geoffrey Ku • 24 Sep 2020
3:53
Sacituzumab govitecan in metastatic urothelial carcinoma: updates on the Phase II study
Yohann Loriot • 23 Sep 2020
3:20
Updates on the DANUBE, KEYNOTE-361 and JAVELIN Studies
Yohann Loriot • 23 Sep 2020
View All Videos
2:31
Axitinib plus pembrolizumab in advanced RCC
Michael Atkins • 26 May 2020
1:15
Q-TWiST of lenvatinib + everolimus in advanced RCC
Chung Han-Lee • 29 May 2020
2:38
Safety outcomes of darolutamide vs apalutamide and enzalutamide in nmCRPC
Neal Shore • 21 May 2020
2:29
COVID-19 and cancer care
Neal Shore • 21 May 2020
View All Videos
2:54
Risk stratification in metastatic seminoma
Peter Albers • 13 Feb 2020
7:53
Growing treatment landscape for advanced bladder cancer
Cora Sternberg • 13 Feb 2020
4:31
Current obstacles in the treatment of urothelial carcinoma
Sima Porten • 13 Feb 2020
1:21
Tracy Rose: RCC highlights
Tracy Rose • 13 Feb 2020
View All Videos

The GU Channel on VJOncology is supported by a grant from Pfizer Inc and Merck KGaA. The supporters have no influence over the production of the content.

If you are interested in becoming a supporter of The Genitourinary (GU) Cancer Channel, please contact us

VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals